prikaz prve stranice dokumenta The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy
  Preuzmi
PDF 620.08 KB
Znanstveni rad - Izvorni znanstveni rad
The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy
Medicina, 58 (2022), 2; 252. https://doi.org/10.3390/medicina58020252
Mikolašević, Ivana; Domislović, Viktor; Krznarić-Zrnić, Irena; Krznarić, Željko; Virović-Jukić, Lucija; Stojsavljević, Sanja; Grgurević, Ivica; Milić, Sandra; Vukoja, Ivan; Puž, Petra; Aralica, Merica; Hauser, Goran

Citirajte ovaj rad

Mikolašević, I., Domislović, V., Krznarić Zrnić, I., Krznarić, Ž., Virović Jukić, L., Stojsavljević, S. ... Hauser, G. (2022). The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. Medicina, 58. (2). doi: 10.3390/medicina58020252

Mikolašević, Ivana, et al. "The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy." Medicina, vol. 58, br. 2, 2022. https://doi.org/10.3390/medicina58020252

Mikolašević, Ivana, Viktor Domislović, Irena Krznarić Zrnić, Željko Krznarić, Lucija Virović Jukić, Sanja Stojsavljević, Ivica Grgurević, et al. "The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy." Medicina 58, br. 2 (2022). https://doi.org/10.3390/medicina58020252

Mikolašević, I., et al. (2022) 'The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy', Medicina, 58(2). doi: 10.3390/medicina58020252

Mikolašević I, Domislović V, Krznarić Zrnić I, Krznarić Ž, Virović Jukić L, Stojsavljević S, i sur.. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. Medicina [Internet]. 08.02.2022. [pristupljeno 21.10.2024.];58(2). doi: 10.3390/medicina58020252

I. Mikolašević, et al., "The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy", Medicina, vol. 58, br. 2, Veljača 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:905710. [Citirano: 21.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:905710
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy
AutorIvana Mikolašević
AutorViktor Domislović
AutorIrena Krznarić-Zrnić
AutorŽeljko Krznarić
AutorLucija Virović-Jukić
AutorSanja Stojsavljević
AutorIvica Grgurević
AutorSandra Milić
AutorIvan Vukoja
AutorPetra Puž
AutorMerica Aralica
AutorGoran Hauser
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background and Objective: This study was conducted to evaluate the diagnostic performance of various biomarkers for steatosis, fibrosis, and inflammation in comparison to a liver biopsy (LB) in patients with nonalcoholic fatty liver disease (NAFLD). Materials and Methods: This was a cross-sectional study that included 135 patients with biopsy-proven NAFLD. Fatty liver index (FLI), hepatic steatosis index (HSI), cell death markers (CK-18 M30 and CK-18 M65), FIB-4 index, NAFLD fibrosis score (NFS), BARD, and AST to platelet ratio index (APRI) were calculated and analysed. Results: FLI, HSI scores, and the cell death biomarkers showed poor diagnostic accuracy for steatosis detection and quantification, with an area under the curve (AUC) of 0.7) for advanced fibrosis, whereas FIB-4, BARD, and NFS scores demonstrated poor performance (AUC < 0.70). However, a combination of FIB-4 and NFS with the cell death biomarkers had moderate accuracy for advanced (≥F3) fibrosis detection, with an AUC of >0.70. Conclusions: In this first study on Croatian patients with NAFLD, serum biomarkers demonstrated poor diagnostic performance for the noninvasive diagnosis of liver steatosis and NASH. APRI and the cell death biomarkers had only moderate accuracy for diagnosing advanced fibrosis, as did the combination of FIB-4 and NFS with the cell death biomarkers. Further studies regarding serum biomarkers for all NAFLD stages are needed.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaMedicina
Brojčani podacivol. 58, br. 2, 252
e-ISSN1648-9144
DOIhttps://doi.org/10.3390/medicina58020252
URN:NBNurn:nbn:hr:184:905710
Datum objave publikacije2022-02-08
URL dokumentahttps://www.mdpi.com/1648-9144/58/2/252
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-03-21 17:34:07